MX364002B - Compuestos y composiciones activadoras de enzima. - Google Patents

Compuestos y composiciones activadoras de enzima.

Info

Publication number
MX364002B
MX364002B MX2015001551A MX2015001551A MX364002B MX 364002 B MX364002 B MX 364002B MX 2015001551 A MX2015001551 A MX 2015001551A MX 2015001551 A MX2015001551 A MX 2015001551A MX 364002 B MX364002 B MX 364002B
Authority
MX
Mexico
Prior art keywords
compositions
compounds
enzyme
activating compounds
cell death
Prior art date
Application number
MX2015001551A
Other languages
English (en)
Other versions
MX2015001551A (es
Inventor
j hergenrother Paul
Steven Roth Howard
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2015001551A publication Critical patent/MX2015001551A/es
Publication of MX364002B publication Critical patent/MX364002B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención provee compuestos y composiciones útiles para la modulación de ciertas enzimas. Los compuestos y composiciones pueden inducir muerte celular, particularmente muerte de célula de cáncer. La invención también provee métodos para la síntesis y uso de los compuestos y composiciones, incluyendo el uso de compuestos y composiciones en terapia para el tratamiento de cáncer e inducción selectiva de apoptosis en células.
MX2015001551A 2012-08-03 2013-08-05 Compuestos y composiciones activadoras de enzima. MX364002B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261679129P 2012-08-03 2012-08-03
PCT/US2013/053648 WO2014022858A1 (en) 2012-08-03 2013-08-05 Enzyme-activating compounds and compositions

Publications (2)

Publication Number Publication Date
MX2015001551A MX2015001551A (es) 2015-10-08
MX364002B true MX364002B (es) 2019-04-10

Family

ID=50028583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001551A MX364002B (es) 2012-08-03 2013-08-05 Compuestos y composiciones activadoras de enzima.

Country Status (12)

Country Link
US (2) US9249116B2 (es)
EP (1) EP2880020B1 (es)
JP (1) JP6265558B2 (es)
KR (1) KR102157912B1 (es)
CN (1) CN104981461B (es)
AU (1) AU2013296187B2 (es)
BR (1) BR112015002357B1 (es)
CA (1) CA2879798C (es)
HK (1) HK1205112A1 (es)
MX (1) MX364002B (es)
RU (1) RU2652989C2 (es)
WO (1) WO2014022858A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134474A2 (en) * 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
US8916705B2 (en) * 2011-10-14 2014-12-23 The Board of Trustees of The University of Illilnois Procaspase-activating compounds and compositions
JP2017538699A (ja) 2014-12-05 2017-12-28 エーエヌ２エイチ ディスカバリー リミテッド パーキンリガーゼ活性化の方法及び組成物
US10350207B2 (en) 2015-06-05 2019-07-16 The Board Of Trustees Of The University Of Illinois PAC-1 combination therapy
KR102637041B1 (ko) 2015-11-12 2024-02-16 현대모비스 주식회사 차량 위치 정보 확인 시스템
EP3463347A4 (en) 2016-06-03 2019-12-18 An2H Discovery Limited TRIAZOLBENZAMID DERIVATIVES AND COMPOSITIONS AND METHODS FOR TREATMENT RELATED TO THIS
CN111491927A (zh) 2017-11-17 2020-08-04 伊利诺伊大学董事会 通过降解双mek信号传导的癌症疗法
US10889553B2 (en) 2017-12-01 2021-01-12 Nysnobio Ireland Dac Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same
CN113727984B (zh) 2019-05-21 2024-03-15 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
CN110759937B (zh) * 2019-11-12 2021-12-28 吉林大学 一种含硼有机电致发光化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
CN101184491A (zh) * 2005-05-26 2008-05-21 伊利诺伊大学评议会 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导
WO2007008529A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
CN101712655B (zh) * 2008-10-08 2012-05-23 秦引林 一种乙酰胺类衍生物及其在制药中的应用
US8778945B2 (en) 2009-02-09 2014-07-15 The Board Of Trustees Of The University Of Illinois Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
CN101565409B (zh) * 2009-03-20 2011-09-07 深圳市湘雅生物医药研究院 哌嗪或高哌嗪草酰肼类化合物及其制备方法和用途
CN101941953B (zh) * 2010-02-10 2013-04-10 深圳市湘雅生物医药研究院 含氮杂环取代的酰肼类化合物及其制备方法和用途
RU2578565C2 (ru) * 2010-12-13 2016-03-27 Басф Се Катализаторы отбеливания
CN102838567B (zh) * 2011-06-23 2014-12-31 深圳市湘雅生物医药研究院 一种苯磺酰或苯甲酰哌嗪类化合物及其制备方法和用途
US8916705B2 (en) * 2011-10-14 2014-12-23 The Board of Trustees of The University of Illilnois Procaspase-activating compounds and compositions

Also Published As

Publication number Publication date
BR112015002357B1 (pt) 2022-03-15
KR102157912B1 (ko) 2020-09-21
HK1205112A1 (en) 2015-12-11
US20160176833A1 (en) 2016-06-23
CA2879798A1 (en) 2014-02-06
US9663482B2 (en) 2017-05-30
AU2013296187A1 (en) 2015-02-26
RU2652989C2 (ru) 2018-05-04
US20150210659A1 (en) 2015-07-30
CN104981461B (zh) 2017-09-29
JP2015524445A (ja) 2015-08-24
KR20150038390A (ko) 2015-04-08
MX2015001551A (es) 2015-10-08
BR112015002357A2 (pt) 2017-07-04
CA2879798C (en) 2022-05-31
AU2013296187B2 (en) 2016-09-29
EP2880020A4 (en) 2016-01-20
RU2015107303A (ru) 2016-09-27
WO2014022858A1 (en) 2014-02-06
EP2880020A1 (en) 2015-06-10
JP6265558B2 (ja) 2018-01-24
CN104981461A (zh) 2015-10-14
US9249116B2 (en) 2016-02-02
EP2880020B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
MX364002B (es) Compuestos y composiciones activadoras de enzima.
PH12018502569A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
TN2015000091A1 (en) Glucosylceramide synthase inhibitors
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2014001218A (es) Tratamiento de cancer de mama.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
IN2014MN01945A (es)
MX2013007268A (es) Activadores de pkm2 bicíclicos.
IL207310A0 (en) Vaccine compositions
IN2014MN01944A (es)
GB2528604A (en) Modulation of asymmetric proliferation
MX350868B (es) Medicamentos y metodos para tratar cancer.
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
TN2013000368A1 (en) Glucosylceramide synthase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration